Prospective Evaluation of Infants With Spinal Muscular Atrophy:
study id #: NCT02831296
condition: Spinal Muscular Atrophy
status: Recruiting
purpose:SPOT SMA is a prospective NIH-supported clinical study targeting pre-symptomatic or recently diagnosed infants and children with Spinal Muscular Atrophy (SMA) types 1, 2, or 3 and their healthy control siblings less than 36 months of age at the time of study enrollment. The main objective of the study is to prospectively collect longitudinal clinical outcomes and provide counseling and education to parents of newly diagnosed children. The study will assess the impact of current standard of care management paradigms and interventions on health outcomes in newly diagnosed SMA infants and children with type 1, 2 or 3 and age appropriate controls. There is no investigational drug and no specific intervention in this study. Rather, the investigators will document outcomes related to current therapies provided to participating subjects, and will educate participants about possible clinical trial opportunities.
results: https://clinicaltrials.gov/ct2/show/results/NCT02831296
last updated: February 04, 2022
-
Spinal Muscular Atrophy With Predominant Lower Extremity (SMA-LED) With no Signs Other Than Pure Motor Symptoms at t...Background: Mutations in the cytoplasmic...
-
Megan A. Waldrop, MDMegan Waldrop, MD, is a Pediatric Neurol...
-
Guidance on Gene Replacement Therapy in Spinal Muscular Atrophy: A Canadian PerspectiveSpinal muscular atrophy (SMA) is the sec...
-
The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular AtrophySpinal muscular atrophy (SMA) is a rare,...
-
Understanding Spinal Muscular Atrophy (SMA)https://www.youtube.com/watch?v=5mI_ZsWk...
-
Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated With NusinersenObjective: To retrospectively evaluate t...
-
Revised Upper Limb Module in Type II And III Spinal Muscular Atrophy: 24-Month ChangesThe aim of the study was to establish 24...